PMID- 23641864
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 10
DP  - 2013 Jul
TI  - Imidafenacin for the treatment of overactive bladder.
PG  - 1383-97
LID - 10.1517/14656566.2013.796930 [doi]
AB  - INTRODUCTION: Imidafenacin (KRP-197/ONO-8025) is the latest antimuscarinic (AM) 
      developed for the treatment of overactive bladder syndrome (OAB) and, at the 
      moment, it is marketed only in Japan. This compound has been developed to improve 
      the tolerability of AM therapy by binding specifically the M3 receptor subtype, 
      thus limiting undesirable adverse events (AEs). AREAS COVERED: This systematic 
      review offers a brief explanation of the mechanism of action and of the 
      pharmacokinetics of imidafenacin and helps readers to understand the clinical 
      efficacy, tolerability, and safety of the compound in the setting of OAB therapy. 
      EXPERT OPINION: Imidafenacin is an AM drug with excellent efficacy, tolerability, 
      and safety. It is indicated for patients with nocturia, nocturnal polyuria, and 
      benign prostatic hyperplasia. This compound, due to its pharmacokinetic 
      properties, gives the opportunity to be easily adjusted in its dosages. Further 
      studies should assess the pharmacokinetics, clinical efficacy, safety, and 
      tolerability of imidafenacin in Caucasian and African populations because this AM 
      agent, at the moment, has been evaluated just in Asian populations. More studies 
      should evaluate and compare efficacy, safety, and tolerability of imidafenacin 
      also with other largely utilized AMs, such as oxybutynin, tolterodine, and 
      fesoterodine, or with the other M3 selective compound, darifenacin.
FAU - Leone Roberti Maggiore, Umberto
AU  - Leone Roberti Maggiore U
AD  - University of Genoa, Institute for Cancer Research, San Martino Hospital, 
      Department of Obstetrics and Gynecology, Genoa, Italy. simone.ferrero@unige.it
FAU - Scala, Carolina
AU  - Scala C
FAU - Venturini, Pier Luigi
AU  - Venturini PL
FAU - Ferrero, Simone
AU  - Ferrero S
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20130506
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Imidazoles)
RN  - 0 (Muscarinic Antagonists)
RN  - XJR8Y07LJO (imidafenacin)
SB  - IM
EIN - Expert Opin Pharmacother. 2014 Feb;15(2):301
MH  - Animals
MH  - Humans
MH  - Imidazoles/pharmacology/*therapeutic use
MH  - Muscarinic Antagonists/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy/metabolism
EDAT- 2013/05/07 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/07 06:00 [entrez]
PHST- 2013/05/07 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - 10.1517/14656566.2013.796930 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Jul;14(10):1383-97. doi: 
      10.1517/14656566.2013.796930. Epub 2013 May 6.